🇺🇸 Paclitaxel and carboplatin in United States

10 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Arthritis — 1 report (10%)
  2. Cervix Carcinoma Stage Iv — 1 report (10%)
  3. Chronic Obstructive Pulmonary Disease — 1 report (10%)
  4. Diabetes Mellitus — 1 report (10%)
  5. Gastrooesophageal Reflux Disease — 1 report (10%)
  6. Metastases To Lung — 1 report (10%)
  7. Migraine — 1 report (10%)
  8. Neutropenia — 1 report (10%)
  9. Neutrophil Count Decreased — 1 report (10%)
  10. Peripheral Vascular Disorder — 1 report (10%)

Source database →

Other Oncology approved in United States

Frequently asked questions

Is Paclitaxel and carboplatin approved in United States?

Paclitaxel and carboplatin does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Paclitaxel and carboplatin in United States?

Chinese Academy of Medical Sciences is the originator. The local marketing authorisation holder may differ — check the official source linked above.